The present application relates to a erythrocyte-derived magnetic immune particle and uses thereof, according to an aspect, the erythrocyte-derived magnetic immune particle include an erythrocyte-derived cell membrane, which may minimize in vivo side effect, and may be used to detect and remove various type of substances (for example, a pathogenic substance, an inflammatory cytokine, blood glucose, a cancer-related substance, and a brain disease-related substance, etc.) from a sample with excellent efficiency, which may be useful for diagnosing, preventing, or treating various type of diseases, including an infectious disease, an inflammatory disease, diabetes, cancer, and brain disease.

The present application relates to a erythrocyte-derived magnetic immune particle and uses thereof, according to an aspect, the erythrocyte-derived magnetic immune particle include an erythrocyte-derived cell membrane, which may minimize in vivo side effect, and may be used to detect and remove various type of substances (for example, a pathogenic substance, an inflammatory cytokine, blood glucose, a cancer-related substance, and a brain disease-related substance, etc.) from a sample with excellent efficiency, which may be useful for diagnosing, preventing, or treating various type of diseases, including an infectious disease, an inflammatory disease, diabetes, cancer, and brain disease.

Method of localizing a sulfhydryl (SH) group containing biomolecule to the surface of a cell membrane by mixing in a volatile reaction buffer a molar excess of the sulfhydryl (SH) group containing biomolecule with a lipid conjugated maleimide of the structure F-S-L as defined in the specification to provide a reaction mix, incubating the reaction mix for a time and at a temperature sufficient to allow all the lipid conjugated maleimide to have reacted with the sulfhydryl (SH) group, and freeze-drying the reaction mix to remove the volatile reaction buffer and provide a reaction product. An aqueous solution of the reaction product is contacted with the cell membrane.

Method of localizing a sulfhydryl (SH) group containing biomolecule to the surface of a cell membrane by mixing in a volatile reaction buffer a molar excess of the sulfhydryl (SH) group containing biomolecule with a lipid conjugated maleimide of the structure F-S-L as defined in the specification to provide a reaction mix, incubating the reaction mix for a time and at a temperature sufficient to allow all the lipid conjugated maleimide to have reacted with the sulfhydryl (SH) group, and freeze-drying the reaction mix to remove the volatile reaction buffer and provide a reaction product. An aqueous solution of the reaction product is contacted with the cell membrane.

The present invention provides novel methods for the detection of antibodies, in particular, blood group antibodies. The methods of this invention may be applied to pre-transfusion blood compatibility testing for the detection of incompatibility between donor units (comprising donor red blood cells (erythrocytes)) and a recipient.

The present invention relates to novel methods for detecting a member of a known binding pair in a sample, including a cell, where one member of the pair (termed the receptor) is expressed by a bacteriophage, which phage is then used to detect the presence of the other member of the pair (termed the ligand or target). Rather than detecting the binding of the phage using antibody-based technology, the present invention relates to detecting marker molecule associated with the phage. In one aspect, the invention relates to identifying an antigen-bearing moiety (e.g., a red blood cell antigen) of interest present on a cell, e.g., a red blood cell, using antibody-displaying bacteriophage, as well as detecting anti-red blood cell auto- or alloantibodies and/or complement in a sample, using antiglobulin reagent-displaying bacteriophage and detecting a marker molecule associated with the phage. In one aspect, the phenotype of the phage is not linked with the genotype of the phage.

The present invention relates to novel methods for detecting a member of a known binding pair in a sample, including a cell, where one member of the pair (termed the receptor) is expressed by a bacteriophage, which phage is then used to detect the presence of the other member of the pair (termed the ligand or target). Rather than detecting the binding of the phage using antibody-based technology, the present invention relates to detecting marker molecule associated with the phage. In one aspect, the invention relates to identifying an antigen-bearing moiety (e.g., a red blood cell antigen) of interest present on a cell, e.g., a red blood cell, using antibody-displaying bacteriophage, as well as detecting anti-red blood cell auto- or alloantibodies and/or complement in a sample, using antiglobulin reagent-displaying bacteriophage and detecting a marker molecule associated with the phage. In one aspect, the phenotype of the phage is not linked with the genotype of the phage.

The present invention is based on the finding that red blood cell antigens can be exploited as a means to detect red blood cells/erythrocytes. Specifically, by identifying red blood cell antigens which are expressed by substantially all red blood cell types, it is possible to provide a method which achieves the reliable detection of red blood cells.

The present disclosure provides compositions, methods, kits and systems for detecting antibodies in a biological sample. In some embodiments, methods/systems are particularly useful for detecting antibodies in patients against pathogen-inactivating compound treated RBCs.

The present disclosure provides compositions, methods, kits and systems for detecting antibodies in a biological sample. In some embodiments, methods/systems are particularly useful for detecting antibodies in patients against pathogen-inactivating compound treated RBCs.